PLEASANTON - Movano Health (NASDAQ:MOVE), a developer of wearable healthcare solutions, is set to meet with the U.S. Food and Drug Administration (FDA) in mid-August to discuss the regulatory path for its EvieMED Ring. The wearable device, which includes a pulse oximetry feature and tracks various wellness metrics, is currently under review for a 510(k) clearance.
The company filed an updated 510(k) submission for the EvieMED Ring on April 21, 2024, with an initial expectation of a regulatory decision by July 2024. However, following requests for clarification from the FDA review team in May and early June, and additional information in late June, the timeline has been extended.
Movano Health provided a draft response to the FDA's inquiries on July 10, 2024, and the upcoming meeting aims to address the wellness aspects of the EvieMED Ring. The company's CEO, John Mastrototaro, expressed a strong commitment to working with the FDA and highlighted the clinical evidence supporting the device's pulse oximetry feature.
The company also announced that it will report its second quarter 2024 financial and operating results on Wednesday, August 14, 2024, after the market close. A conference call and live audio webcast will follow to discuss the results and provide a business update.
Founded in 2018, Movano Health is focused on providing medical-grade data through wearable technology. The Evie Ring, part of the company's product lineup, is designed to offer insights into an individual's health data. The company's proprietary technology aims to enable proactive health monitoring and management across various patient populations.
This news article is based on a press release statement from Movano Health.
In other recent news, Movano Health reported its Q1 2024 earnings, highlighting advancements in its product offerings and clinical trials. The company showcased the ongoing development of its Evie Ring and submitted clinical trial results for its Evie Med ring to the FDA, with a 510(k) clearance decision expected in July 2024.
Despite shipping 5,305 units and generating $852,000 in revenue, Movano Health faced an operating loss of $5.8 million. However, a recent $24 million private placement is set to bolster its marketing, enterprise launches, and clinical trial acceleration.
With $24.8 million in cash reserves, Movano Health is actively engaged in strategic discussions to enhance its product's reach in the healthcare market. The company has temporarily halted new orders of Evie Rings to stabilize inventory levels but plans to re-ignite its direct-to-consumer approach following the expected FDA clearance. Movano Health is also exploring strategic partnerships in pharmaceutical, medical device, and payer channels.
InvestingPro Insights
As Movano Health (NASDAQ:MOVE) gears up for a pivotal meeting with the FDA regarding the EvieMED Ring, investors and stakeholders are closely watching the company's financial health and market performance. Recent data from InvestingPro shows a mixed picture that could influence expectations and strategy.
On the financial front, Movano Health's market capitalization stands at a modest $35.59 million. This underlines the company's status as a small-cap enterprise, which often entails higher volatility and risk. The company's struggles are further reflected in its gross profit margin, which has been negative over the last twelve months as of Q1 2024, at -42.61%. This indicates that the company is spending more to produce its goods than it's able to earn back in sales, a trend that stakeholders hope will reverse as the company scales and optimizes its operations.
InvestingPro Tips suggest that Movano Health is not profitable over the last twelve months and is quickly burning through cash, which raises concerns about its financial sustainability. However, it's worth noting that the company holds more cash than debt on its balance sheet, providing some cushion against short-term financial pressures. For investors considering the stock's future, these factors are crucial, especially as the company navigates the costly process of securing FDA clearance for its wearable technology.
Despite these challenges, the stock has seen a strong return over the last month, with a 22.79% price total return, hinting at investor optimism or a potential market correction. This could be a sign of growing confidence in the company's prospects or a response to broader market movements. For those interested in a deeper dive into Movano Health's financials and market performance, there are additional InvestingPro Tips available on the platform.
As the date of the FDA meeting approaches, Movano Health's financial health and stock performance will remain key areas of focus. With additional insights and tips available on InvestingPro, stakeholders can stay informed and make data-driven decisions.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.